Experts are rapidly examining retatrutide, a promising drug from Eli Lilly, as a significant advance in body reduction . Distinct from many earlier approaches, retatrutide is a twin-action agonist targeting equally GLP-1 and GIP, substances that influence hunger and blood sugar balance. Prelimin